Human antibodies to Ebola virus glycoprotein

Patent metadata

Field	Value
Publication number	US-11530255-B2
Application number	US-202017039557-A
Country	US
Kind code	B2
Filing date	Sep 30, 2020
Priority date	Jan 26, 2015
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

First claim

What is claimed is:

1. An isolated recombinant antibody or antigen-binding fragment thereof that specifically binds to Ebola virus (EBOV) and/or an Ebola virus glycoprotein (EBOV-GP), comprising:
(a) a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence as set forth in SEQ ID NO: 20 with no more than one amino acid substitution; an HCDR2 amino acid sequence as set forth in SEQ ID NO: 22 with no more than one amino acid substitution; an HCDR3 amino acid sequence as set forth in SEQ ID NO: 24 with no more than one amino acid substitution; a light chain complementarity determining region LCDR1 amino acid sequence as set forth in SEQ ID NO: 28 with no more than one amino acid substitution; an LCDR2 amino acid sequence as set forth in SEQ ID NO: 30 with no more than one amino acid substitution; and an LCDR3 amino acid sequence as set forth in SEQ ID NO: 32 with no more than one amino acid substitution;
(b) an HCDR1 amino acid sequence of SEQ ID NO: 68 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 70 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 72 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 76 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 78 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 80 with no more than one amino acid substitution; or
(c) an HCDR1 amino acid sequence of SEQ ID NO: 148 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 150 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 152 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 156 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 158 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 160 with no more than one amino acid substitution.

2. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1 , comprising:
(a) a heavy chain variable region (HCVR) amino acid sequence having 95% sequence identity to SEQ ID NO: 18; and a light chain variable region (LCVR) amino acid sequence having 95% sequence identity to SEQ ID NO: 26;
(b) an HCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 74; or
(c) an HCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 95% sequence identity to SEQ ID NO: 154.

3. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1 , comprising:
(a) an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 26;
(b) an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 74; or
(c) an HCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 98% sequence identity to SEQ ID NO: 154.

4. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1 , comprising:
(a) an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 18; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 26;
(b) an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 66; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 74; or
(c) an HCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 146; and an LCVR amino acid sequence having 99% sequence identity to SEQ ID NO: 154.

5. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1 , comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 3 amino acid substitutions.

6. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1 , comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 3 amino acid substitutions.

7. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1 , comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 3 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 3 amino acid substitutions.

8. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1 , comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 18 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 26 with no more than 2 amino acid substitutions.

9. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1 , comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 66 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 74 with no more than 2 amino acid substitutions.

10. The isolated recombinant antibody or antigen-binding fragment thereof of claim 1 , comprising:
an HCVR having an amino acid sequence of SEQ ID NO: 146 with no more than 2 amino acid substitutions; and an LCVR amino acid sequence of SEQ ID NO: 154 with no more than 2 amino acid substitutions.

11. The isolated antibody of claim 1 , wherein the antibody inhibits entry of Ebola virus into a host cell.

12. A pharmaceutical composition comprising one or more isolated monoclonal antibodies or antigen-binding fragments thereof that bind specifically to EBOV according to claim 1 , and a pharmaceutically acceptable carrier or diluent.

13. The pharmaceutical composition of claim 12 , wherein the isolated monoclonal antibody or an antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 20 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 22 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 24 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 28 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 30 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 32 with no more than one amino acid substitution, and a pharmaceutically acceptable carrier or diluent.

14. The pharmaceutical composition of claim 12 , wherein the isolated monoclonal antibody or an antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 68 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 70 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 72 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 76 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 78 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 80 with no more than one amino acid substitution.

15. The pharmaceutical composition of claim 12 , wherein the isolated monoclonal antibody or an antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 148 with no more than one amino a

Assignees

• Regeneron Pharma

Inventors

• Kyratsous Christos
• Olson William
• Mason Peter
• Stahl Neil

Classifications

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title